Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
RRM1 6240 GEMCITABINE CHEMBL888 inhibitor ClearityFoundationBiomarkers, TdgClinicalTrial, ClearityFoundationClinicalTrial, GuideToPharmacologyInteractions, CIViC, DrugBank 17131328, 16807441, 17636467, 16966686, 17065054, 16708051, 24595080, 19543324, 24647522, 23038758
RRM1 6240 IMEXON CHEMBL146428 DrugBank
RRM1 6240 TEZACITABINE CHEMBL2105467 inhibitor ChemblInteractions
RRM1 6240 MOTEXAFIN GADOLINIUM CHEMBL3544910 TdgClinicalTrial
RRM1 6240 GEMCITABINE HYDROCHLORIDE CHEMBL1637 inhibitor ChemblInteractions
RRM1 6240 CLADRIBINE CHEMBL1619 inhibitor DrugBank 16316309, 9923554, 19576186, 17852710, 19715446
RRM1 6240 CLOFARABINE CHEMBL1750 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank 17139284, 17016423, 18780321, 19519505, 19576186, 20631817, 18728851, 17852710, 15230627
RRM1 6240 HYDROXYUREA CHEMBL467 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank 15075397, 20005847, 14583450, 20462199
RRM1 6240 FLUDARABINE CHEMBL1568 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
RRM1 6240 GALLIUM NITRATE CHEMBL1200983 inhibitor ChemblInteractions
RRM1 6240 VINORELBINE BASE CHEMBL553025 CIViC 24647522, 23038758
RRM1 6240 FLUDARABINE PHOSPHATE CHEMBL1096882 inhibitor ChemblInteractions
RRM1 6240 PHENYLTHIOUREA CHEMBL263376 PharmGKB
RRM1 6240 PACLITAXEL CHEMBL428647 CIViC 23038758
RRM1 6240 DOCETAXEL CHEMBL92 CIViC 24647522

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
RRM1 rs1561876 GG cladribine efficacy yes The GG genotype (reported as CC in the paper) was associated with lower intracellular cytarabine levels at day 1 of therapy, inferior response after the first course of remission induction therapy, poor event-free survival and a greater risk of relapse. No multiple testing adjustments were performed: 7 SNPs were investigated. Genotype GG is associated with decreased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotypes AA + AG. 24024897 1183700190
RRM1 rs1042919 AT cladribine efficacy yes The AT genotype was associated with lower intracellular cytarabine levels in leukemic blasts at day 1 and 2 of therapy, and poor event-free survival. Risk of relapse was not significantly different. No multiple testing adjustments were performed: 7 SNPs were investigated. Genotype AT is associated with decreased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotype AA. 24024897 1183700199
RRM1 rs2898950 AC + CC cladribine efficacy yes Less patients with a complete response after the first induction therapy were seen in the AA genotype group. No multiple testing adjustments were performed: 7 SNPs were investigated. Genotypes AC + CC is associated with increased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotype AA. 24024897 1183700205
RRM1 rs1042858 AA carboplatin efficacy no Genotype AA is not associated with response to carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG. 20226083 1184175254
RRM1 rs1042858 AA gemcitabine "efficacy","toxicity" no Tumor response to therapy, progression free survival, and risk of neutropenia development did not significantly differ between genotype groups. Genotype AA is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AG + GG. 20665488 981793989
RRM1 rs183484 AC gemcitabine "efficacy","toxicity" yes Patients with the AC genotype had shorter progression free survival than patients with either the AA or the CC genotypes. However, tumor response to therapy and risk of developing neutropenia did not significantly differ between genotype groups. There were four SNPs in this study that, when taken together, affected progression free survival: rs183484, rs2072671, rs760370, and rs9937. Using patients with 0 or 1 variant as reference, patients with 2 variants had an increased HR of 1.79 (P = 0.004) and patients with 3-4 variants has an increased HR of 3.25 (P < 0.001). Genotype AC is associated with decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AA + CC. 20665488 981794008
RRM1 rs720106 TT cisplatin efficacy yes The authors analyzed the effect of genotypes on overall survival in patients treated with gemcitabine/cisplatinum (n=139) and in patients treated with taxane/cisplatinum (n= 159). Although no association was found between overall survival and the TT genotype at rs720106 (RRM1) alone, an association was found when combining the effect of the TT genotype at rs720106 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine/cisplatin, but not in patients treated with taxane/cisplatin. Genotype TT is associated with decreased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT. 21642870 1183960616
RRM1 rs2284449 TT cisplatin efficacy yes The authors analyzed the effect of genotypes on overall survival in patients treated with gemcitabine/cisplatinum (n=139) and in patients treated with taxane/cisplatinum (n= 159). Although no association was found between overall survival and the TT genotype at rs2284449 (RRM1) alone, an association was found when combining the effect of the TT genotype at rs2284449 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine/cisplatin, but not in patients treated with taxane/cisplatin. Genotype TT is associated with decreased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung. 21642870 1183960601
RRM1 rs725518 GG cisplatin efficacy no The authors analyzed the effect of genotype in RRM1 on overall survival in patients treated with gemcitabine/cisplatinum (n=139) and in patients treated with taxane/cisplatinum (n= 159). After adjustment for confounding variables (weight loss, ECOG performance status, 2nd line treatment and radiation therapy) the effect of the genotype at rs725518 was not found to be significantly associated with shorter survival in any patient. Genotype GG is not associated with response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG. 21642870 1183960644
RRM1 rs232043 AA cisplatin efficacy yes The authors analyzed the effect of genotypes on overall survival in patients treated with gemcitabine/cisplatinum (n=139) and in patients treated with taxane/cisplatinum (n= 159). Although no association was found between overall survival and the AA genotype at rs232043 (RRM1) alone, an association was found when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine/cisplatin, but not in patients treated with taxane/cisplatin. Genotype AA is associated with decreased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG. 21642870 1183960611
RRM1 rs3817657 TT cisplatin efficacy no The authors analyzed the effect of genotype in CMPK1 on overall survival in patients treated with gemcitabine/cisplatinum (n=139) and in patients treated with taxane/cisplatinum (n= 159). After adjustment for confounding variables (weight loss, ECOG performance status, 2nd line treatment and radiation therapy) the effect of the genotype at rs3817657 was not found to be significantly associated with shorter survival in any patient. Genotype TT is not associated with response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT. 21642870 1183960659
RRM1 rs7940013 CC cisplatin efficacy no The authors analyzed the effect of genotype in RRM1 on overall survival in patients treated with gemcitabine/cisplatinum (n=139) and in patients treated with taxane/cisplatinum (n= 159). After adjustment for confounding variables (weight loss, ECOG performance status, 2nd line treatment and radiation therapy) the effect of the genotype at rs7940013 was not found to be significantly associated with shorter survival in any patient. Genotype CC is not associated with response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT. 21642870 1183960647
RRM1 rs11030918 TT cisplatin efficacy no The authors analyzed the effect of genotype in RRM1 on overall survival in patients treated with gemcitabine/cisplatinum (n=139) and in patients treated with taxane/cisplatinum (n= 159). After adjustment for confounding variables (weight loss, ECOG performance status, 2nd line treatment and radiation therapy) the effect of the genotype at rs11030918 was not found to be significantly associated with shorter survival in any patient. Genotype TT is not associated with response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT. 21642870 1183960634
RRM1 rs11030918 CT gemcitabine efficacy yes The CT is associated with improved response to gemcitabine therapy only when it is part of a haplotype with AC at rs12806698. 65.5% of patients with the CT/AC haplotype at rs11030918 and rs12806698 were "responders" (were in complete or partial remission) while 42.6% of all other haplotypes combined were responders. Non-responders had stable or progressive disease. Genotype CT is associated with increased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + TT. 18483375 1184175348
RRM1 rs11030918 CT + TT ara-CTP metabolism/PK yes Genotypes CT + TT is associated with decreased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotype CC. 30088438 1449752066
RRM1 rs12806698 CC cisplatin efficacy no The authors analyzed the effect of genotype in RRM1 on overall survival in patients treated with gemcitabine/cisplatinum (n=139) and in patients treated with taxane/cisplatinum (n= 159). After adjustment for confounding variables (weight loss, ECOG performance status, 2nd line treatment and radiation therapy) the effect of the genotype at rs12806698 was not found to be significantly associated with shorter survival in any patient. Genotype CC is not associated with response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC. 21642870 1183960639
RRM1 rs12806698 AC carboplatin efficacy yes Patients with the AC genotype had the longest duration of progression free survival (30.7 weeks) compared to patients with the AA (24.7 weeks) or CC (23.3 weeks) genotypes. There was no difference in "chemotherapy response" between groups. Chemotherapy response was classified as either partial response (PD), stable disease (SD), or progressive disease (PD). Genotype AC is associated with increased response to carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + CC. 20226083 1184175245
RRM1 rs12806698 AC gemcitabine efficacy yes The AC genotype is associated with improved response to gemcitabine therapy only when it is part of a haplotype with CT at rs11030918. 65.5% of patients with the CT/AC haplotype at rs11030918 and rs12806698 were "responders" (were in complete or partial remission) while 42.6% of all other haplotypes combined were responders. Non-responders had stable or progressive disease. Genotype AC is associated with increased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + CC. 18483375 1184175360
RRM1 rs9937 AA gemcitabine efficacy yes Patients with the AA genotype had shorter progression free survival than patients with either the AG or the GG genotype. However, tumor response to therapy did not significantly differ between genotype groups. This study presented this SNP as rs3177016, but dbSNP has merged that rsID with rs9937. There were four SNPs in this study that, when taken together, affected progression free survival: rs183484, rs2072671, rs760370, and rs9937. Using patients with 0 or 1 variant as reference, patients with 2 variants had an increased HR of 1.79 (P = 0.004) and patients with 3-4 variants has an increased HR of 3.25 (P < 0.001). Genotype AA is associated with decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AG + GG. 20665488 981793996
RRM1 rs9937 AA carboplatin efficacy no Genotype AA is not associated with response to carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG. 20226083 1184175240
RRM1 rs183484 CC cisplatin efficacy no The authors analyzed the effect of genotype in RRM1 on overall survival in patients treated with gemcitabine/cisplatinum (n=139) and in patients treated with taxane/cisplatinum (n= 159). After adjustment for confounding variables (weight loss, ECOG performance status, 2nd line treatment and radiation therapy) the effect of the genotype at rs11030918 was not found to be significantly associated with shorter survival in any patient. Genotype CC is not associated with response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC. 21642870 1183960654